1. Home
  2. BEAM vs GLP Comparison

BEAM vs GLP Comparison

Compare BEAM & GLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • GLP
  • Stock Information
  • Founded
  • BEAM 2017
  • GLP 2005
  • Country
  • BEAM United States
  • GLP United States
  • Employees
  • BEAM N/A
  • GLP N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • GLP Oil Refining/Marketing
  • Sector
  • BEAM Health Care
  • GLP Energy
  • Exchange
  • BEAM Nasdaq
  • GLP Nasdaq
  • Market Cap
  • BEAM 1.7B
  • GLP 1.8B
  • IPO Year
  • BEAM 2020
  • GLP 2005
  • Fundamental
  • Price
  • BEAM $17.46
  • GLP $51.00
  • Analyst Decision
  • BEAM Strong Buy
  • GLP Hold
  • Analyst Count
  • BEAM 10
  • GLP 1
  • Target Price
  • BEAM $48.56
  • GLP $56.00
  • AVG Volume (30 Days)
  • BEAM 2.4M
  • GLP 35.8K
  • Earning Date
  • BEAM 08-05-2025
  • GLP 08-07-2025
  • Dividend Yield
  • BEAM N/A
  • GLP 5.92%
  • EPS Growth
  • BEAM N/A
  • GLP N/A
  • EPS
  • BEAM N/A
  • GLP 2.60
  • Revenue
  • BEAM $60,272,000.00
  • GLP $17,827,598,000.00
  • Revenue This Year
  • BEAM N/A
  • GLP $38.58
  • Revenue Next Year
  • BEAM $17.18
  • GLP $17.34
  • P/E Ratio
  • BEAM N/A
  • GLP $19.49
  • Revenue Growth
  • BEAM N/A
  • GLP 3.74
  • 52 Week Low
  • BEAM $13.53
  • GLP $37.00
  • 52 Week High
  • BEAM $35.25
  • GLP $60.00
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 39.16
  • GLP 46.30
  • Support Level
  • BEAM $16.65
  • GLP $48.72
  • Resistance Level
  • BEAM $21.40
  • GLP $51.42
  • Average True Range (ATR)
  • BEAM 1.00
  • GLP 1.46
  • MACD
  • BEAM -0.35
  • GLP -0.07
  • Stochastic Oscillator
  • BEAM 13.89
  • GLP 47.28

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About GLP Global Partners LP Common Units representing Limited Partner Interests

Global Partners LP is a limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the Wholesale segment.

Share on Social Networks: